TriSalus Life Sciences (NASDAQ:TLSI) Trading Up 1.3% – Time to Buy?

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) rose 1.3% on Monday . The company traded as high as $3.33 and last traded at $3.21. Approximately 237,997 shares traded hands during trading, a decline of 70% from the average daily volume of 796,421 shares. The stock had previously closed at $3.17.

Analysts Set New Price Targets

TLSI has been the topic of a number of research reports. Lake Street Capital reduced their price objective on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Weiss Ratings lowered TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Finally, Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, TriSalus Life Sciences currently has an average rating of “Hold” and a consensus target price of $7.50.

TriSalus Life Sciences Price Performance

The business has a 50-day simple moving average of $3.90 and a 200 day simple moving average of $4.99. The stock has a market cap of $197.16 million, a P/E ratio of -2.28 and a beta of 0.49. The company has a current ratio of 5.78, a quick ratio of 5.46 and a debt-to-equity ratio of 2.58.

Insider Buying and Selling at TriSalus Life Sciences

In related news, CEO Mary T. Szela purchased 39,682 shares of TriSalus Life Sciences stock in a transaction on Friday, May 15th. The shares were purchased at an average price of $2.59 per share, for a total transaction of $102,776.38. Following the transaction, the chief executive officer owned 1,065,215 shares of the company’s stock, valued at approximately $2,758,906.85. This represents a 3.87% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mats Wahlstrom acquired 60,000 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was acquired at an average cost of $2.53 per share, for a total transaction of $151,800.00. Following the completion of the purchase, the director directly owned 147,555 shares in the company, valued at $373,314.15. This trade represents a 68.53% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have purchased 719,682 shares of company stock worth $1,804,176 and have sold 30,150 shares worth $119,849. Corporate insiders own 16.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its stake in shares of TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of TriSalus Life Sciences in the 2nd quarter valued at about $47,000. Invesco Ltd. acquired a new position in shares of TriSalus Life Sciences in the 4th quarter valued at about $72,000. Abel Hall LLC acquired a new position in shares of TriSalus Life Sciences in the 4th quarter valued at about $73,000. Finally, HighMark Wealth Management LLC acquired a new position in shares of TriSalus Life Sciences in the 4th quarter valued at about $75,000. 2.58% of the stock is owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.